



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

SEP 6 2001

2110 01 SEP 10 09:41

Re: Angiomax
Docket No. 01E-0213

The Honorable Q. Todd Dickinson
Director of U.S. Patent and Trademark Office
Commissioner for Patents
Box Pat. Ext.
Washington, D.C. 20231

Dear Director Dickinson:

This is in regard to the application for patent term extension for U.S. Patent No. 5,196,404 filed by The Medicine Company under 35 U.S.C. § 156. The human drug product claimed by the patent is Angiomax (bivalirudin), which was assigned new drug application (NDA) No. 20-873.


A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in *Glaxo Operations UK Ltd. v. Quigg*, 706 F. Supp. 1224 (E.D. Va. 1989), *aff'd*, 894 F. 2d 392 (Fed. Cir. 1990).

The NDA was approved on December 15, 2000, which makes the submission of the patent term extension application on February 14, 2001, untimely within the meaning of 35 U.S.C. § 156(d)(1), which requires the patent term restoration application to be submitted within 60 days of the product's approval.

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,


Jane A. Axelrad

Associate Director for Policy
Center for Drug Evaluation and Research

cc: Paul Granger, Esq.
The Medicine Company
One Cambridge Center
Cambridge, MA 02142

01E-0213

LET 2